Wave Life Sciences completed its corporate redomiciliation from Singapore to Delaware. The company’s common stock began trading on NASDAQ under the existing 'WVE' ticker on August 10, 2026. Management anticipates no material impact on day-to-day operations or staffing levels.
Analysts lowered the 2026 consensus revenue estimate from $59 million to $52 million. This revised forecast represents a 20% decline compared to the previous 12 months. The consensus price target for the stock subsequently fell 13% to $19.06.